

Melanoma Tumor Board Conference (MELCO) - 10/2/2023
10/2/2023 4:00:00 PM - 10/2/2023 5:00:00 PM

By texting in your attendance, you will be awarded the maximum number of CE credits. If you wish to claim less than the maximum CE credits, please contact ContinuingEducation@mdanderson.org

Target Audience:

Professions: Physician (MD or DO), Nurse - RN, Physician Assistant, Student or Trainee

Learning Objectives:

- 1 Discuss Signal Transduction Pathway Targeted Therapy and strategies to overcome Inhibitor Refractory Melanoma.
- 2 Interpret genetic mutations and molecular targets involving Melanoma progression, metastasis and drug resistant therapy.
- 3 Identify subtypes of cutaneous melanomas and uveal melanomas and apply appropriate management strategies, according to disease stage and tumor mutation status.

Accreditation:



In support of improving patient care, The University of Texas MD Anderson Cancer Center, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Surgery CC Credit:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for purpose of granting ABS credit.

Commercial Support:

No commercial support has been received for this activity.

Disclosure of Financial Relationships:

MD Anderson Continuing Professional Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty & Planner Disclosure:

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Rodabe N. Amaria, MD	Activity Director	Grant or research support-Novartis Pharmaceuticals Corporation Grant or research support-Merck Sharp & Dohme

		Corp. (any division) Grant or research support-Bristol-Myers Squibb Company Grant or research support-lovance Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation Grant or research support-Obsidian Grant or research support-OnKure Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company Membership on Advisory Committees or Review Panels, Board Membership, etc.-lovance Membership on Advisory Committees or Review Panels, Board Membership, etc.-Nektar (Relationship has ended) - 07/24/2023
Jeffrey Gershenwald, MD	Activity Co-Director	Consulting Fee-Merck Sharp & Dohme Corp. (any division) Consulting Fee-Regeneron Pharmaceuticals, Inc. (Relationship has ended) - 09/29/2023
Ryan Goepfert, MD	Other Planning Committee Member	Nothing to disclose - 09/29/2023
B. Ashleigh Guadagnolo, MD, MPH	Activity Co-Director, Faculty	Nothing to disclose - 04/06/2023
Victor G Prieto, MD, PhD, USCAP, ASDP, ISDP, CAP, ASCP	Other Planning Committee Member	Consulting Fee-Myriad Consulting Fee-Orlucent Consulting Fee-Castle Biosciences, Inc. - 09/07/2023
Madhavi Patnana, MD	Other Planning Committee Member	Nothing to disclose - 05/17/2023
Natalie J Jackson, FNP-C, APRN	Other Planning Committee Member	Nothing to disclose - 10/24/2022
Jennifer McQuade, MD	Other Planning Committee Member	Honoraria-Merck Sharp & Dohme Corp. (any division) - 09/29/2023